Skip to main content
Premium Trial:

Request an Annual Quote

Investment Firm Unloads Stake in Genomica

NEW YORK, Aug. 3 – An investment firm responsible in part for providing seed money for Genomica Corporation has sold its nearly 3 percent stake in the company, it said on Friday. 

Harris & Harris Group, based in New York, sold the 731,111 shares it held for a total price of $1.5 million and earned roughly $2.5 million in net proceeds.  The investment firm said it filed a total long-term net capital gain on the sale of slightly more than $1 million.

Genomica, based in Boulder, Colo., develops and markets software products and services, designed to enable pharmaceutical and biotechnology researchers to accelerate the drug discovery and development process. 

Harris & Harris Group, which became a founding investor in Genomica in 1996 after it was spun off from Cold Spring Harbor Laboratory, said it plans to use its net proceeds “in other private equity situations.”

Shares of Genomica slipped 0.05 to 3.15 in early-afternoon Nasdaq trading. The company plans to hold an investor teleconference to report its second-quarter earnings on Aug. 8.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.